The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart attack or death, a new study says.GLP-1 ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor ...

Stroke was the fourth leading cause of death in the US last year, accounting for 162,600 deaths, according to preliminary data.

Empagliflozin, or Empa, is a medication often used to help people with type 2 diabetes manage their blood sugar. Now, ...

It is estimated that more than 5.6 million people in the UK are living with diabetes, with 90 per cent suffering from type 2 ...

The connection between CVD and diabetes cannot be understated, as diabetes impacts CV health and heart conditions affect ...

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

The use of SGLT2 inhibitors vs sulfonylurea was associated with a reduced risk for incident gout and MACE among patients with type 2 diabetes with/at risk for gout.

Sotagliflozin is an oral dual sodium-glucose co-transporter types 1 and 2 (SGLT1/SGLT2) inhibitor. The FDA panel voted against the approval of sotagliflozin for patients with type 1 diabetes and ...

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. The loss of insulin leads to the ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are a relatively new group of medications originally developed ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...